Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Discount contracts: Germany's misguided attempt at cost-cutting

This article was originally published in Scrip

Executive Summary

It is extremely easy to be cynical about what are often perceived to be immense profits generated by the research-based pharmaceutical industry. Perhaps in the past it was easy to fall in line with general criticisms, partly because of reciprocally beneficial deals made with between manufacturers and companies or medical professionals. However, the introduction of self regulation and codes of practice have largely eradicated these agreements. Increasingly, profits are being ploughed back into research and development as the emergence of new chemical entities dries up.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC003906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel